NASDAQ: EXEL

Exelixis (EXEL) Stock Analysis & Forecast

Nov 13 close

$69.00−0.84 (−1.2%)

Gekko Brief

AI summaryNov 9 close

Exelixis moved higher this week on third-quarter results showing revenue and GAAP net income rising year-over-year, driven by the cabozantinib franchise, with full-year 2026 revenue guidance maintained even as the company lowered its effective tax-rate range. The stock also touched an all-time high of $73.49, and continued coverage has highlighted progress on zanzalintinib alongside Exelixis' international revenue exposure.

The shares closed at $71.74, up 3.1% on the day, sitting above both the 50-day average of $61.27 and the 200-day average of $51.70, with the 50-day above the 200-day. The GekkoIndex reads 44.9, placing EXEL in the Distribution zone. Despite the recent strength, price remains 24.7% below the Gekko Fair Value of $95.25.

The next earnings date falls on 9 February 2027, 91 days out and beyond a typical 20-trading-day holding window, with the prior report on 5 August 2026 showing an EPS beat of $0.82 versus $0.75 estimated, though the shares reacted -6.8% afterward. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows, and one trailblazer holder is noted. Seasonally, the next 20 trading days have averaged -0.2% over 5 years, rising in 4 of them, which is worth noting alongside the current Distribution reading.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Exelixis price vs fair value

▲$92.75$69.00Nov ’25May ’26Nov ’26
Close $69.00200-day averageGekko Fair Value $92.75

Exelixis quick facts

Market cap
$17.34B
P/E ratio
20.9
Forward P/E
16.7
EPS, TTM
$3.34
Revenue, TTM
$2.50B
Profit margin
35.4%
Dividend yield
—
Beta
0.42
Volume
1.51M avg 2.68M
1-year return
+58.3%
Typical daily move
±3.7%
Typical 20-day move
±6.1%
50-day average
$62.29
200-day average
$52.24
Next earnings
Feb 9 after close
Shares outstanding
244.0M
52-week range
$39.71$73.69

Exelixis swing-trade checklist

Exelixis scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $69.00 is above the 50-day ($62.29) and 200-day ($52.24) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    53.2, Neutral

    Reading 53.2 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    25.6% below

    Price is 25.6% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 86 days

    Next report Feb 9, 2027, 86 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    0.0% on average

    From this point in the calendar, the next 20 trading days averaged 0% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Exelixis stock chart and price history

Exelixis closed at $69.00 on Nov 13, 2026, +58.3% over the past year, inside a 52-week range of $39.71 to $73.69.

Close50-day average200-day averageVolume
Exelixis share price, past year, with 50-day and 200-day moving averages and volume$40$50$60DecJan 2026FebMarAprMayJunJulAugSepOctNov69.00

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+9.8%
3 months
+31.9%
6 months
+37.6%
1 year
+58.3%
The full EXEL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open EXEL in Gekko

Follow Exelixis through every session

Put EXEL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track EXEL in GekkoFree for 7 days. No credit card required.

About Exelixis

Exelixis works in cancer treatment, developing and selling drugs aimed at fighting the disease within the United States. It markets CABOMETYX for advanced kidney cancer patients who have already had anti-angiogenic therapy, and COMETRIQ for a form of metastatic thyroid cancer; both draw on the same underlying compound, cabozantinib, which blocks several kinases tied to tumor growth. The company also sells COTELLIC, used alongside other treatments for advanced melanoma, and MINNEBRO, a blood pressure medication cleared for use in Japan. Beyond these approved products, Exelixis is advancing several experimental compounds targeting solid tumors and blood cancers through its research pipeline.

The company relies heavily on collaboration, holding research and licensing agreements with a range of pharmaceutical and biotech partners that support both its marketed drugs and its pipeline candidates. These partnerships span companies involved in drug discovery, antibody technology, and manufacturing, reflecting a business model built around shared development efforts rather than working in isolation.

Exelixis traces its origins to 1994, when it was founded under the name Exelixis Pharmaceuticals, Inc., before adopting its current name in February 2000. The company is headquartered in Alameda, California, and its shares are listed on the NASDAQ under the ticker EXEL.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
exelixis.com

Exelixis GekkoIndex: the smart money zone

Exelixis’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.2, in the Neutral zone, up 6.5 points over five sessions.

010053.2Neutral

Up 6.5 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying22+0.3%+1.6%+5.9%+9.9%
Accumulation147+2.0%+3.2%+5.4%+11.4%
Neutral (current zone)482+0.6%+1.5%+3.3%+8.6%
Distribution49+1.2%+1.6%+1.0%−0.3%
Selling2Too few readings yet

Average EXEL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the EXEL price, zone by zone.Track EXEL in Gekko

Is Exelixis stock overvalued? Gekko Fair Value

Exelixis trades 25.6% below Gekko Fair Value of $92.75, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Exelixis shares are worth, recalculated every trading day.

$92.75

Gekko Fair Value, Nov 14, 2026

25.6% Undervalued

At the end of Aug 2026 the price was 2.1% above the estimate.

Gekko Fair ValueShare price, month end
$93$69Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open EXEL in Gekko

Exelixis insider and Congress trading

No open-market insider purchases were filed for Exelixis, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for EXEL in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every EXEL insider filing, plotted on the chart in Gekko.Open EXEL in Gekko

Congress trades last 90 days

No trades in EXEL were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for EXEL, plotted on the chart in Gekko.Open EXEL in Gekko

Buybacks

Exelixis has been buying back its own shares.

Latest authorization
$750.0M, May 5, 2026
Bought back, quarter ended Oct 2, 2026
$250.0M
As a share of market cap
1.44%
Trailing four quarters
$1.26B

From company filings.

Hedge funds and billionaires quarter ended Dec 31

1of the funds Gekko tracks holds EXEL.

0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Exelixis earnings: next date and track record

Exelixis reports on Feb 9, 2027, after the close (86 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±10.1%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+13.8%Oct ’24−2.1%Feb ’25+20.7%May ’25−19.0%Jul ’25+6.1%Nov ’25−2.3%Feb ’26+10.3%May ’26−6.8%Aug ’26

Last earnings call, Aug 5, 2026 AI summary

What they said
Exelixis reported solid Q2 2026 results driven by the cabozantinib (cabo) franchise, with total revenues of approximately $629 million and cabozantinib franchise net product revenues of $573 million. CABOMETYX net product revenue grew 10% year-over-year and TRx volume grew 12% versus Q2 2025. GAAP net income was approximately $212 million ($0.85 basic, $0.82 diluted). Management reiterated confidence in cabozantinib’s long-term trajectory while prioritizing zanzalintinib (zanza) as the company’s next franchise opportunity, highlighting seven ongoing/imminent pivotal trials and an NDA under regulatory review for zanza plus atezo in colorectal cancer with a PDUFA target in early December. The company updated its estimate for full-year 2026 gross-to-net deductions for the cabozantinib franchise to 30%-31% and noted modestly slower growth in 2026 driven by a more gradual ramp in the NET indication. Management emphasized execution, ongoing trial initiations (e.g., STELLAR-316, STELLAR-311, STELLAR-201), potential second-wave trials in 2027, and continued share repurchases.
Guidance
Updated financial guidance reflects modestly slower growth in 2026 due to a more gradual NET ramp. The company updated its estimate for full-year 2026 gross-to-net deductions for the cabozantinib franchise to between 30% and 31%. Zanzalintinib NDA (STELLAR-303) review with a PDUFA target in early December 2026. No explicit numeric revenue or EPS guidance provided on the call beyond these updates.
Risks flagged
Risks discussed or noted include clinical and regulatory risk (ongoing NDA review, potential non-significant endpoints—non-liver mets subgroup in STELLAR-303), enrollment and event-rate variability in clinical trials, potential cannibalization of commercial patients by trials in smaller tumor types, ANDA and 505(b)(2) regulatory/IP challenges related to generic/alternative formulations, gross-to-net pressure (higher deductions, co-pay assistance changes, 340B utilization), and competitive dynamics in oncology.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 5, 2026$0.82
est $0.75
+9.3%$628.7M
est $636.4M
−1.2%−6.8%
May 5, 2026$0.87
est $0.77
+13.0%$610.8M
est $607.5M
+0.5%+10.3%
Feb 10, 2026$0.94
est $0.77
+22.1%$598.7M
est $596.5M
+0.4%−2.3%
Nov 4, 2025$0.78
est $0.69
+12.5%$597.8M
est $590.2M
+1.3%+6.1%
Jul 28, 2025$0.75
est $0.65
+15.4%$568.3M
est $594.9M
−4.5%−19.0%
May 13, 2025$0.62
est $0.37
+69.1%$555.4M
est $499.6M
+11.2%+20.7%
Feb 11, 2025$0.55
est $0.49
+11.8%$566.8M
est $563.2M
+0.6%−2.1%
Oct 29, 2024$0.40
est $0.35
+14.3%$539.5M
est $556.6M
−3.1%+13.8%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Exelixis stock forecast and analyst price targets

Analysts’ average 12-month price target for Exelixis is $61.57, −10.8% from the last close, from 13 firms rating the stock in the last 90 days.

$61.57consensus 12-month target, −10.8% from the last close
Low $41High $78
Buy4
Hold8
Sell1

Each firm’s latest rating in the last 90 days: 13 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Morgan StanleyHold, maintained$57−17.4%
Nov 9RBC CapitalHold, maintained$58−15.9%
Nov 5Leerink PartnersHold, maintained$58−15.9%
Nov 2H.C. WainwrightBuy, reiterated$78+13.0%
Oct 30BarclaysHold, maintained$54−21.7%
+3.3%average 20-day move after past Neutral readings
0.0%average move over the next 20 trading days in the last 5 years
±3.7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Exelixis seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Exelixis averaged 0.0% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−5.9%2021−3.9%2022+10.4%2023−0.1%2024−0.6%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−0.8%2 of 5
Next 10 trading days−0.6%2 of 5
Next 15 trading days−0.4%3 of 5
Next 20 trading days0.0%1 of 5
Next 30 trading days+2.4%3 of 5

For scale, EXEL’s typical 20-trading-day move in either direction is about 6.1%.

Exelixis market cap and key statistics

Exelixis’s market cap is $17.34B, with a P/E ratio of 20.9 and revenue of $2.50B over the last twelve months.

Valuation

Market cap
$17.34B
P/E ratio
20.9
Forward P/E
16.7
EPS, TTM
$3.34
Gekko Fair Value
$92.75

Trading

Volume
1.51M
Avg volume, 20 days
2.68M
52-week high
$73.69
52-week low
$39.71
Shares outstanding
244.0M

Financials

Revenue, TTM
$2.50B
Profit margin
35.4%
Return on equity
44.3%
Quarterly earnings growth, YoY
+23.2%

Risk and income

Beta
0.42
Typical daily move
±3.7%
Typical 20-day move
±6.1%

Exelixis peers

Exelixis’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Exelixis stock FAQ

What is Exelixis’s market cap?

Exelixis’s market cap is $17.34B at the Nov 13, 2026 close of $69.00, with 244.0M shares outstanding. The shares trade on a P/E ratio of 20.9.

What is the Exelixis stock forecast?

The consensus analyst 12-month price target for Exelixis is $61.57, −10.8% from the last close. Of the 13 firms that rated the stock in the last 90 days, 4 rate it a buy, 8 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.

Is Exelixis stock overvalued or undervalued?

On Gekko’s estimate Exelixis is undervalued: the Nov 13, 2026 close of $69.00 is 25.6% below Gekko Fair Value of $92.75. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Exelixis report earnings next?

Exelixis is expected to report on Feb 9, 2027, after the market closes (86 days away). Analysts expect earnings of $0.96 per share on revenue of $658.4M. Exelixis beat the earnings estimate in 8 of its last 8 reports, moving 10.1% on average across the report.

What is Exelixis’s 52-week high and low?

Exelixis’s 52-week high is $73.69 and its 52-week low is $39.71; it closed at $69.00 on Nov 13, 2026, +58.3% over the past year.

Is Exelixis stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and earnings risk), 2 as mixed (gekkoindex and seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Exelixis the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.